Core Viewpoint - Lyell Immunopharma (LYEL) has been upgraded to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Lyell Immunopharma indicate an improvement in the company's underlying business, likely leading to increased stock prices as investors respond positively [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2024, Lyell Immunopharma is expected to earn -$0.78 per share, reflecting a year-over-year change of 16.1% [8]. - Over the past three months, the Zacks Consensus Estimate for Lyell Immunopharma has increased by 22.6%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 5% receiving a 'Strong Buy' rating, highlighting Lyell Immunopharma's strong position in this regard [9][10]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, underscoring the effectiveness of the rating system [7].

Core Insights - Lyell Immunopharma is advancing its pipeline of next-generation CAR T-cell therapies, specifically focusing on IMPT-314 for aggressive large B-cell lymphoma, which is set to enter pivotal trials [1][2][4] Pipeline Focus - The company is dedicated to developing CAR T-cell therapies that aim to achieve higher response rates and longer durations of response for patients with hematologic malignancies and solid tumors [3] - IMPT-314 is designed to target B-cells expressing either CD19, CD20, or both, utilizing a dual-targeting approach to enhance treatment efficacy compared to existing therapies [4][12] Clinical Data and Development Plans - Initial clinical data from 23 patients indicated an overall response rate of 94% and a complete response rate of 71% in the 3rd-line+ setting, with a median follow-up of 6.3 months [14] - The company plans to initiate pivotal trials for IMPT-314 in the 3rd-line+ setting in 2025 and in the 2nd line by early 2026 [6][17] Financial Outlook - Lyell expects a net cash use of $175 million to $185 million for 2025, which will extend its cash runway into 2027, supporting multiple clinical milestones [9] - The company is streamlining operations and discontinuing the development of LYL119 to focus resources on IMPT-314 and next-generation solid tumor CAR T-cell programs [8] Upcoming Milestones - Additional data from the ongoing Phase 1-2 trial is expected to be presented in mid-2025, including more mature data from the 3rd line+ cohort and initial data from the 2nd line cohort [7] - The first IND application for a new solid tumor CAR T-cell product candidate is anticipated to be submitted in 2026 [8]

Core Viewpoint - Lyell Immunopharma (LYEL) has experienced significant selling pressure, resulting in a 31.2% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1]. Group 1: Stock Performance and Technical Analysis - The stock is currently in oversold territory, indicated by an RSI reading of 28.44, suggesting that the heavy selling may be exhausting itself [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30 [2]. - Technical analysis indicates that stocks oscillate between overbought and oversold states, and the RSI can signal potential price reversals [3]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a consensus among sell-side analysts to raise earnings estimates for LYEL, resulting in a 0.9% increase in the consensus EPS estimate over the last 30 days [7]. - LYEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8].

Core Viewpoint - Lyell Immunopharma (LYEL) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - For the fiscal year ending December 2024, Lyell Immunopharma is projected to earn -$0.80 per share, reflecting a 14% change from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for Lyell Immunopharma has increased by 6.3%, indicating a positive trend in earnings expectations [8]. Institutional Investor Influence - Institutional investors play a role in the relationship between earnings estimates and stock price movements, as they adjust their valuations based on these estimates, leading to significant buying or selling actions [4]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Lyell Immunopharma to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Financial Performance - Lyell Immunopharma reported a net loss of $44.6 million for Q3 2024, an improvement from a net loss of $50.9 million in Q3 2023, representing a 10.5% decrease in losses year-over-year[4]. - GAAP net loss for Q3 2024 was $44.583 million, a decrease from $50.853 million in Q3 2023[13]. - Non-GAAP net loss for Q3 2024 was $37.064 million, compared to $43.043 million in Q3 2023[13]. Expenses - Research and development (R&D) expenses for Q3 2024 were $39.5 million, down from $43.8 million in Q3 2023, reflecting a decrease of 7.8% primarily due to reduced personnel-related expenses[5]. - General and administrative (G&A) expenses decreased to $11.8 million in Q3 2024 from $15.5 million in Q3 2023, a reduction of 24.2% driven by lower non-cash stock-based compensation[5]. - Total operating expenses for Q3 2024 were $50.5 million, a decrease from $59.0 million in Q3 2023, reflecting a reduction of 8.5%[10]. - Stock-based compensation expense for Q3 2024 was $7.622 million, down from $10.516 million in Q3 2023[13]. - Total research and development expenses for the nine months ended September 30, 2024, were $122.935 million, down from $135.950 million in the same period of 2023[14]. - Total general and administrative expenses for the nine months ended September 30, 2024, were $37.519 million, compared to $53.816 million in the same period of 2023[16]. Cash and Assets - Cash, cash equivalents, and marketable securities totaled $460.7 million as of September 30, 2024, down from $562.7 million as of December 31, 2023, indicating a decrease of 18.1%[6]. - Lyell's total assets as of September 30, 2024, were $619.2 million, down from $750.0 million as of December 31, 2023, indicating a decrease of 17.4%[11]. Clinical Development - The company plans to initiate a pivotal clinical trial for IMPT-314 in 2025, targeting patients with relapsed/refractory large B-cell lymphoma who have not yet been exposed to CAR T-cell therapy[2]. - Initial data from the Phase 1-2 trial of IMPT-314 is expected to be presented at the ASH 2024 Annual Meeting on December 9, 2024[2]. - Lyell's acquisition of ImmPACT Bio is expected to enhance the clinical pipeline, particularly with the addition of IMPT-314, which has shown promising Phase 1 clinical data[1]. - The company is advancing LYL119, a next-generation ROR1-targeted CAR T-cell product candidate, which is entering Phase 1 clinical development[2]. Changes in Liabilities - The change in estimated fair value of success payment liabilities for Q3 2024 was $(103,000), compared to $(2.706 million) in Q3 2023[13].

Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3rd line setting with B-cell non-Hodgkin lymphoma who have not yet been exposed to CAR T-cell therapySumant Ramachandra, M.D., Ph.D., MBA, appointed to Lyell’s Board of Directors SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) --  Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell ...

Company Overview - Lyell Immunopharma is a clinical-stage T-cell reprogramming company focused on developing cell therapies for solid tumors and hematologic malignancies [3] - The company has three product candidates in or entering Phase 1 clinical development [3] - Lyell's proprietary technology addresses T-cell exhaustion and lack of durable stemness to improve clinical outcomes [3] - The company is headquartered in South San Francisco, California with additional facilities in Seattle and Bothell, Washington [3] Upcoming Event - Lyell's President & CEO, Lynn Seely, MD, will participate in a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1, 2024, at 11:50 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible after the live event [2]

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that members of its senior management team will present and participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th at 10:45 am Eastern Time H.C. Wainw ...

For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical trials or a Food and Drug Administration approval to rush a stock into the headlines rapidly. Yet, as quickly as these securities go up, so too can they come down, resulting in biotech stocks to sell. In these cases, investors who act quickly or see through the hype can avoid portfolio losses while maximizing ...

Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells) First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumors No significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic diseas ...